$Clinical Management of Relapsed/Refractory Hemophagocytic Lymphohistiocytosis in Adult Patients: A Review of Current Strategies and Emerging Therapies$
Código QR

Clinical Management of Relapsed/Refractory Hemophagocytic Lymphohistiocytosis in Adult Patients: A Review of Current Strategies and Emerging Therapies

Halil Yildiz,1 Sarah Bailly,2 Eric Van Den Neste,2 Jean Cyr Yombi1 1Departement of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint Luc, Bruxelles, Belgique; 2Departement of Hematology, Cliniques Universitaires Saint Luc, Bruxelles, BelgiqueCorrespondence: Halil YildizDepart...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yildiz H, Bailly S, Van Den Neste E, Yombi JC
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	aemophagocytic lymphohistiocytosis refractory doxorubicin etoposide methylprednisolone regimen hematopoietic stem cell transplantation emapalumab ruxolutinib alemtuzumab macrophage activating syndrome Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/c7d7a3626ec343db94f6287997856bef
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c7d7a3626ec343db94f6287997856bef
record_format	dspace
spelling	oai:doaj.org-article:c7d7a3626ec343db94f6287997856bef2021-12-02T14:22:18ZClinical Management of Relapsed/Refractory Hemophagocytic Lymphohistiocytosis in Adult Patients: A Review of Current Strategies and Emerging Therapies1178-203Xhttps://doaj.org/article/c7d7a3626ec343db94f6287997856bef2021-04-01T00:00:00Zhttps://www.dovepress.com/clinical-management-of-relapsedrefractory-hemophagocytic-lymphohistioc-peer-reviewed-article-TCRMhttps://doaj.org/toc/1178-203XHalil Yildiz,1 Sarah Bailly,2 Eric Van Den Neste,2 Jean Cyr Yombi1 1Departement of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint Luc, Bruxelles, Belgique; 2Departement of Hematology, Cliniques Universitaires Saint Luc, Bruxelles, BelgiqueCorrespondence: Halil YildizDepartement of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint Luc, 10 Avenue Hippocrate, Bruxelles, 1200, BelgiqueEmail halil.yildiz@uclouvain.beIntroduction: Haemophagocytic lymphohistiocytosis (HLH) is a severe disorder with high mortality. The aim of this review is to update clinical management of relapsed/refractory HLH in adults, with a focus on current and new therapies.Methods: We searched relevant articles in Embase and PUBMED with the MESH term “hemophagocytic lymphohistiocytosis; refractory; relapsing; adult.”Results: One hundred eight papers were found; of these, 22 were retained for this review. The treatment of HLH in adult is based on the HLH-94 regimen. The response rate is lower than in pediatric patients, and 20– 30% are refractory to this therapy. DEP regimen and allogenic hematopoietic stem cell transplantation (HSCT) are associated with complete response and partial response in 27% and 49.2%, respectively. However, many patients fail to achieve a stable condition before HSCT, and mortality is higher in them. New drugs have been developed, such as emapalumab, ruxolitinib, and alemtuzumab, and they may be used as bridges to the curative HSCT. They are relatively well tolerated and have few or mild side effects. With these agents, the rate of partial response ranges from 14.2% to 100%, while the rate of complete response is highly variable according to study and medication used. The number of patients who achieved HSCT ranged from 44.8% to 77%, with a survival rate of 55.9% to 100%. However, the populations in these studies are mainly composed of mixed-age patients (pediatric and adult patients), and studies including only adult patients are scarce.Conclusion: Relapsed or refractory HLH in adult patients is associated with poor outcome, and consolidation with HSCT may be required in some cases. Mortality related to HSCT is mainly due to active HLH disease before HSCT and post HSCT complications. New drugs, such as empalumab, ruxolitinib, and alemtuzumab are interesting since these agents may be used as bridges to HSCT with increases in the numbers of patients proceeding to HSCT and survival rate.Keywords: haemophagocytic lymphohistiocytosis, refractory, doxorubicin, etoposide, methylprednisolone regimen, hematopoietic stem cell transplantation, emapalumabYildiz HBailly SVan Den Neste EYombi JCDove Medical Pressarticleaemophagocytic lymphohistiocytosisrefractorydoxorubicinetoposidemethylprednisolone regimenhematopoietic stem cell transplantationemapalumabruxolutinibalemtuzumabmacrophage activating syndromeTherapeutics. PharmacologyRM1-950ENTherapeutics and Clinical Risk Management, Vol Volume 17, Pp 293-304 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	aemophagocytic lymphohistiocytosis refractory doxorubicin etoposide methylprednisolone regimen hematopoietic stem cell transplantation emapalumab ruxolutinib alemtuzumab macrophage activating syndrome Therapeutics. Pharmacology RM1-950
spellingShingle	aemophagocytic lymphohistiocytosis refractory doxorubicin etoposide methylprednisolone regimen hematopoietic stem cell transplantation emapalumab ruxolutinib alemtuzumab macrophage activating syndrome Therapeutics. Pharmacology RM1-950 Yildiz H Bailly S Van Den Neste E Yombi JC Clinical Management of Relapsed/Refractory Hemophagocytic Lymphohistiocytosis in Adult Patients: A Review of Current Strategies and Emerging Therapies
description	Halil Yildiz,1 Sarah Bailly,2 Eric Van Den Neste,2 Jean Cyr Yombi1 1Departement of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint Luc, Bruxelles, Belgique; 2Departement of Hematology, Cliniques Universitaires Saint Luc, Bruxelles, BelgiqueCorrespondence: Halil YildizDepartement of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint Luc, 10 Avenue Hippocrate, Bruxelles, 1200, BelgiqueEmail halil.yildiz@uclouvain.beIntroduction: Haemophagocytic lymphohistiocytosis (HLH) is a severe disorder with high mortality. The aim of this review is to update clinical management of relapsed/refractory HLH in adults, with a focus on current and new therapies.Methods: We searched relevant articles in Embase and PUBMED with the MESH term “hemophagocytic lymphohistiocytosis; refractory; relapsing; adult.”Results: One hundred eight papers were found; of these, 22 were retained for this review. The treatment of HLH in adult is based on the HLH-94 regimen. The response rate is lower than in pediatric patients, and 20– 30% are refractory to this therapy. DEP regimen and allogenic hematopoietic stem cell transplantation (HSCT) are associated with complete response and partial response in 27% and 49.2%, respectively. However, many patients fail to achieve a stable condition before HSCT, and mortality is higher in them. New drugs have been developed, such as emapalumab, ruxolitinib, and alemtuzumab, and they may be used as bridges to the curative HSCT. They are relatively well tolerated and have few or mild side effects. With these agents, the rate of partial response ranges from 14.2% to 100%, while the rate of complete response is highly variable according to study and medication used. The number of patients who achieved HSCT ranged from 44.8% to 77%, with a survival rate of 55.9% to 100%. However, the populations in these studies are mainly composed of mixed-age patients (pediatric and adult patients), and studies including only adult patients are scarce.Conclusion: Relapsed or refractory HLH in adult patients is associated with poor outcome, and consolidation with HSCT may be required in some cases. Mortality related to HSCT is mainly due to active HLH disease before HSCT and post HSCT complications. New drugs, such as empalumab, ruxolitinib, and alemtuzumab are interesting since these agents may be used as bridges to HSCT with increases in the numbers of patients proceeding to HSCT and survival rate.Keywords: haemophagocytic lymphohistiocytosis, refractory, doxorubicin, etoposide, methylprednisolone regimen, hematopoietic stem cell transplantation, emapalumab
format	article
author	Yildiz H Bailly S Van Den Neste E Yombi JC
author_facet	Yildiz H Bailly S Van Den Neste E Yombi JC
author_sort	Yildiz H
title	Clinical Management of Relapsed/Refractory Hemophagocytic Lymphohistiocytosis in Adult Patients: A Review of Current Strategies and Emerging Therapies
title_short	Clinical Management of Relapsed/Refractory Hemophagocytic Lymphohistiocytosis in Adult Patients: A Review of Current Strategies and Emerging Therapies
title_full	Clinical Management of Relapsed/Refractory Hemophagocytic Lymphohistiocytosis in Adult Patients: A Review of Current Strategies and Emerging Therapies
title_fullStr	Clinical Management of Relapsed/Refractory Hemophagocytic Lymphohistiocytosis in Adult Patients: A Review of Current Strategies and Emerging Therapies
title_full_unstemmed	Clinical Management of Relapsed/Refractory Hemophagocytic Lymphohistiocytosis in Adult Patients: A Review of Current Strategies and Emerging Therapies
title_sort	clinical management of relapsed/refractory hemophagocytic lymphohistiocytosis in adult patients: a review of current strategies and emerging therapies
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/c7d7a3626ec343db94f6287997856bef
work_keys_str_mv	AT yildizh clinicalmanagementofrelapsedrefractoryhemophagocyticlymphohistiocytosisinadultpatientsareviewofcurrentstrategiesandemergingtherapies AT baillys clinicalmanagementofrelapsedrefractoryhemophagocyticlymphohistiocytosisinadultpatientsareviewofcurrentstrategiesandemergingtherapies AT vandennestee clinicalmanagementofrelapsedrefractoryhemophagocyticlymphohistiocytosisinadultpatientsareviewofcurrentstrategiesandemergingtherapies AT yombijc clinicalmanagementofrelapsedrefractoryhemophagocyticlymphohistiocytosisinadultpatientsareviewofcurrentstrategiesandemergingtherapies
_version_	1718391515375468544

Clinical Management of Relapsed/Refractory Hemophagocytic Lymphohistiocytosis in Adult Patients: A Review of Current Strategies and Emerging Therapies

Ejemplares similares